These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38272537)

  • 1. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records.
    Doran W; Tunnicliffe L; Muzambi R; Rentsch CT; Bhaskaran K; Smeeth L; Brayne C; Williams DM; Chaturvedi N; Eastwood SV; Dunachie SJ; Mathur R; Warren-Gash C
    BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38272537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
    Newby D; Linden AB; Fernandes M; Molero Y; Winchester L; Sproviero W; Ghose U; Li QS; Launer LJ; Duijn CMV; Nevado-Holgado AJ
    BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36109050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes.
    Wu CY; Wang C; Saskin R; Shah BR; Kapral MK; Lanctôt KL; Herrmann N; Cogo-Moreira H; MacIntosh BJ; Edwards JD; Swardfager W
    J Intern Med; 2024 Jan; 295(1):68-78. PubMed ID: 37747779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
    Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
    Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
    Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
    Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
    Currie CJ; Poole CD; Gale EA
    Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
    Pai YW; Chen IC; Lin JF; Chen XH; Chen HH; Chang MH; Huang JA; Lin CH
    Diabetes Obes Metab; 2024 Nov; 26(11):5420-5430. PubMed ID: 39248211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
    Salas J; Morley JE; Scherrer JF; Floyd JS; Farr SA; Zubatsky M; Barthold D; Dublin S
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):623-634. PubMed ID: 32363681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
    Shi Q; Liu S; Fonseca VA; Thethi TK; Shi L
    BMJ Open; 2019 Jul; 9(7):e024954. PubMed ID: 31366635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
    Lu CH; Yang CY; Li CY; Hsieh CY; Ou HT
    Diabetologia; 2018 Mar; 61(3):562-573. PubMed ID: 29138876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant prescribing for atrial fibrillation and risk of incident dementia.
    Cadogan SL; Powell E; Wing K; Wong AY; Smeeth L; Warren-Gash C
    Heart; 2021 Dec; 107(23):1898-1904. PubMed ID: 34645643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
    Currie CJ; Holden SE; Jenkins-Jones S; Morgan CL; Voss B; Rajpathak SN; Alemayehu B; Peters JR; Engel SS
    Diabetes Obes Metab; 2018 Apr; 20(4):821-830. PubMed ID: 29119713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
    Scherrer JF; Morley JE; Salas J; Floyd JS; Farr SA; Dublin S
    Ann Fam Med; 2019 Jul; 17(4):352-362. PubMed ID: 31285213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.